In a paper published in National Science Review, an international team of scientists report a coordination nanomedicine ...
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
In common with UltraCAR-T, Precigen’s AdenoVerse Immunotherapy platform is poised to disrupt the gene therapy space. The AdenoVerse platform is differentiated from other gene therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback